New hope for leukemia patients: Chemo-Free treatment shows promise

NCT ID NCT04747912

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new chemotherapy-free treatment for adults with a specific type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The treatment combines three drugs: inotuzumab ozogamicin, dasatinib, and dexamethasone. The goal is to see if this combination can help patients achieve complete remission faster and with fewer side effects than standard chemotherapy. The trial is currently recruiting 25 participants who have not yet received treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

inotuzumab ozogamicin (Besponsa) combined with dasatinib and dexamethasone

What this could lead to

If successful, this could offer a chemotherapy-free option for newly diagnosed Ph+ ALL, leading to faster and deeper remission without the harsh side effects of traditional chemo.

What could go wrong

This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The drug combination may still cause side effects, and long-term safety and effectiveness are not yet known.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Chicago Medical Center

    RECRUITING

    Chicago, Illinois, 60615, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••